A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis

• Status: Completed
• Trial end date: 2008-06-17
• Target enrollment: 0
• Participant gender: Female

Summary

This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Denosumab

Criteria

Inclusion Criteria:

• Women who are 60 to 90 years of age may be eligible to participate

• Bone mineral density (BMD) T-Score at hip or spine must be less than -2.5

Exclusion Criteria:

• BMD T-Score at the hip or the spine of less than -4.0

• Patients with any severe or more than two moderate vertebral fractures on spinal x-ray at entry